STAAR Surgical (NASDAQ:STAA) Stock Passes Above 200-Day Moving Average - What's Next?

Key Points

• STAAR Surgical shares passed above their 200‑day moving average, trading as high as $27.86 and last at $27.75 versus a 200‑day MA of $22.47 (50‑day MA $21.41); market cap is about $1.38 billion.
• Quarterly results missed expectations: STAAR reported a ($0.37) EPS vs. $0.14 expected and revenue of $57.8M vs. $75.5M consensus, though revenue was up 18% year‑over‑year and margins remained negative.
• Analyst and insider signals are mixed: the consensus rating is "Hold" with a $19.93 price target (below current price), while Broadwood Partners bought 316,017 shares at ~$18.61 and insiders acquired 670,213 shares in the last 90 days.

STAAR Surgical Company (NASDAQ:STAA - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $22.47 and traded as high as $27.86. STAAR Surgical shares last traded at $27.75, with a volume of 706,705 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on STAA shares. Canaccord Genuity Group raised shares of STAAR Surgical from a "hold" rating to a "buy" rating and boosted their price target for the stock from $22.00 to $27.00 in a research note on Thursday, April 9th. Wells Fargo & Company dropped their price objective on shares of STAAR Surgical from $30.75 to $16.00 and set an "equal weight" rating for the company in a report on Thursday, March 5th. Stifel Nicolaus cut their target price on shares of STAAR Surgical from $19.00 to $18.00 and set a "hold" rating for the company in a research report on Wednesday, March 4th. Jefferies Financial Group reduced their target price on STAAR Surgical from $28.00 to $21.50 and set a "buy" rating on the stock in a research note on Wednesday, January 28th. Finally, Wedbush lifted their price target on STAAR Surgical from $21.00 to $26.00 and gave the stock a "neutral" rating in a research note on Thursday, April 9th. Two investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, STAAR Surgical currently has a consensus rating of "Hold" and a consensus price target of $19.93.

STAAR Surgical Stock Up 1.1%

The firm has a market capitalization of $1.38 billion, a P/E ratio of -17.02 and a beta of 1.20. The business's 50-day simple moving average is $21.41 and its 200 day simple moving average is $22.47.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of $0.14 by ($0.51). STAAR Surgical had a negative return on equity of 10.03% and a negative net margin of 33.60%.The business had revenue of $57.80 million during the quarter, compared to the consensus estimate of $75.54 million. The business's revenue for the quarter was up 18.0% on a year-over-year basis. Sell-side analysts predict that STAAR Surgical Company will post -0.03 earnings per share for the current year.

Insider Transactions at STAAR Surgical

In related news, Director Broadwood Partners, L.P. acquired 316,017 shares of STAAR Surgical stock in a transaction dated Friday, March 13th. The shares were purchased at an average cost of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the purchase, the director owned 16,123,842 shares of the company's stock, valued at $300,064,699.62. This represents a 2.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have bought 670,213 shares of company stock worth $12,266,249 in the last ninety days. Corporate insiders own 0.59% of the company's stock.

Institutional Investors Weigh In On STAAR Surgical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank grew its position in STAAR Surgical by 3.6% during the 3rd quarter. Amalgamated Bank now owns 14,609 shares of the medical instruments supplier's stock worth $393,000 after acquiring an additional 514 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in STAAR Surgical by 58.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,669 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 614 shares during the last quarter. Invesco Ltd. lifted its position in STAAR Surgical by 0.6% in the third quarter. Invesco Ltd. now owns 150,896 shares of the medical instruments supplier's stock valued at $4,055,000 after purchasing an additional 956 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of STAAR Surgical by 2.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 52,535 shares of the medical instruments supplier's stock valued at $1,214,000 after purchasing an additional 1,234 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of STAAR Surgical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier's stock worth $518,000 after purchasing an additional 1,267 shares during the last quarter. Institutional investors own 96.70% of the company's stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.